← Back to Search

Omega-3 Fatty Acids

Omega-3 Supplements for Cardiovascular Disease (FAS Trial)

N/A
Waitlist Available
Led By Marie-Claude Vohl, Ph.D.
Research Sponsored by Laval University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Healthy men and women aged between 18 to 50 years
Free of any thyroid or metabolic disorders requiring treatment such as diabetes, hypertension, severe dyslipidemia, and coronary heart disease
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial looks at the effects of a type of fish oil on metabolic risk factors, and whether individual genetic variation affects those results.

Who is the study for?
This trial is for healthy adults aged 18-50 with a BMI of 25-40kg/m2 and normal triglyceride levels. Participants should not smoke, drink alcohol regularly, or have thyroid/metabolic disorders like diabetes or severe dyslipidemia. Pregnant/nursing women and those on certain medications are excluded.
What is being tested?
The study is testing the effects of n-3 PUFA (Omega-3 fatty acid) supplements on metabolic risk factors related to cardiovascular disease, considering genetic variations that might affect how individuals respond to these fats.
What are the potential side effects?
While specific side effects aren't listed, Omega-3 supplements may sometimes cause mild digestive issues, fishy aftertaste, and increased bleeding tendency in some people.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 50 years old and healthy.
Select...
I do not have diabetes, high blood pressure, severe cholesterol issues, or heart disease.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: capsules omega-3Experimental Treatment1 Intervention
Omega-3 supplementation (3g EPA+DHA/d)

Find a Location

Who is running the clinical trial?

Laval UniversityLead Sponsor
430 Previous Clinical Trials
178,195 Total Patients Enrolled
Marie-Claude Vohl, Ph.D.Principal InvestigatorInstitute of Nutraceutical and Functional Foods (INAF), Laval University

Media Library

n-3 PUFA Supplementation (Omega-3 Fatty Acids) Clinical Trial Eligibility Overview. Trial Name: NCT01343342 — N/A
Cardiovascular Disease Research Study Groups: capsules omega-3
Cardiovascular Disease Clinical Trial 2023: n-3 PUFA Supplementation Highlights & Side Effects. Trial Name: NCT01343342 — N/A
n-3 PUFA Supplementation (Omega-3 Fatty Acids) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01343342 — N/A
~12 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top